Adjunctive treatment with quetiapine for major depressive disorder: are the benefits of treatment worth the risks?

BMJ. 2015 Mar 4:350:h569. doi: 10.1136/bmj.h569.

Authors

Tamara Pringsheim¹, David Gardner², Scott B Patten³

Affiliations

¹ Department of Clinical Neurosciences, Psychiatry and Community Health Sciences, University of Calgary, Calgary, AB, Canada tmprings@ucalgary.ca.
² Department of Psychiatry and Pharmacy, Dalhouise University, Halifax, NS, Canada.
³ Department of Community Health Sciences and Psychiatry, University of Calgary.

PMID: 25739588
DOI: 10.1136/bmj.h569

No abstract available

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Antidepressive Agents / therapeutic use*
Antipsychotic Agents / adverse effects*
Depressive Disorder, Major / drug therapy*
Dibenzothiazepines / adverse effects*
Drug Therapy, Combination
Dyslipidemias / chemically induced*
Humans
Hyperglycemia / chemically induced*
Quetiapine Fumarate
Risk Assessment
Treatment Outcome
Weight Gain*

Substances

Antidepressive Agents
Antipsychotic Agents
Dibenzothiazepines
Quetiapine Fumarate